Jefferies Predicts Stellar Outlook For Medivation Inc (MDVN) and MDV3100

Today Jefferies analysts increased their price target on Medivation, Inc’s (NASAQ: MDVN) from $95 to $97 based on expectation that their cancer drug MDV3100 will reach $2 billion in sales by 2020.

Jefferies analysts are optimistic that drug will continue to do will in clinical trails. MDV3100 has shown positive results in a Phase III trail (AFFIRM) for post-cehmotherapy castrate-resistant prostate cancer (CRPC), and is currently in Phase III (PREVAIL).

Jefferies analysts conducted a proprietary survey involving urologists and oncologists showing strong MDV3100 pre and post-chemo uptake.

Jefferies has a BUY rating Medivation (NASDAQ: MDVN).

For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.

Shares of Medivation closed at $74.82 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform